1. World Health Organization. Colorectal cancer. 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/colorectal- cancer.
2.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. 2022. CA Cancer J Clin 2022; 72: 7-33.
3.
Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023; 72: 338-344.
4.
Cardoso R, Guo F, Heisser T, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol 2021; 22: 1002-1013.
5.
Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. Precis Oncol 2023; 7: 16. DOI: 10.1038/s41698-023-00353-4.
6.
Gmeiner HW. Recent advances in therapeutic strategies to improve colorectal cancer treatment. Cancers (Basel) 2024; 16: 1029. DOI: 10.3390/cancers16051029.
7.
Cervantes A, Adam R, Roselló S, et al.; ESMO Guidelines Committee. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34: 10-32.
8.
NCCN Clinical Practice Guidelines in Oncology, Colon Cancer, Version 2.2024.
9.
Johnson D, Chee CE, Wong W, et al. Current advances in targeted therapy for metastatic colorectal cancer – clinical translation and future directions. Cancer Treat Rev 2024; 125. DOI: 10.1016/ j.ctrv.2024.102700.
10.
Modest DP, Pant SB, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 2019; 109: 70-83.
11.
Ikoma N, Raghav K, Chang G. An update on randomized clinical trials in metastatic colorectal carcinoma. Surg Oncol Clin N Am 2017; 26: 667-687.
12.
Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: where to fit the target? World J Gastroenterol 2014; 20: 1993-2004.
13.
Schmoll HJ, Mann J, Meinert F, et al. Efficacy and quality of life for FOLFOX/bevacizumab +/– irinotecan in first-line metastatic colorectal cancer – final results of the AIO CHARTA trial. Br J Cancer 2024; 130: 233-241.
14.
Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1355-1369.
15.
Aparicio T, Ghiringhelli F, Boige V, et al. Bevacizumab maintenance versus no maintenance during chemotherapy-free intervals in metastatic colorectal cancer: a randomized phase III trial (PRODIGE 9). J Clin Oncol 2018; 36: 674-681.
16.
Modest DP, Pant S, Sartore-Bianchi A. Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 2019; 109: 70-83.
17.
Albuquerque J, Neto da Silva D, Padrão T, et al. Loss of RAS mutations in liquid biopsies of patients with multi-treated metastatic colorectal cancer. Oncologist 2024; 29: 337-344.
18.
Heinemann V, Von Weikersthal FL, Decker T, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. Br J Cancer 2021; 124: 587-594.
19.
Qin S, Li J, Wang L, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol 2018; 36: 3031-3039.
20.
Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.
21.
Rivera F, Karthaus M, Hecht JR, et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 2017; 32: 1179-1190.
22.
Oberstein PE, Moreno v, Raghav KPS, et al. Amivantamab monotherapy in relapsed/refract. Meeting Abstract: 2024 ASCO Gastrointestinal Cancers Symposium; 2024.
23.
Kuboki Y, Yaeger R, Fakih MG, et al. 315O sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase Ib full expansion cohort. Ann Oncol 2022; 33: S680-S681. DOI: 10.1016/j.annonc.2022.07.453.
24.
Klempner SJ, Weiss JA, Pelster MS, et al. LBA24 KRYSTAL-1: updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation. Ann Oncol 2022; 33: S1391. DOI: 10.1016/j.annonc.2022.08.020.
25.
Guerrero P, Albarrán V, San Román M, et al. BRAF inhibitors in metastatic colorectal cancer and mechanisms of resistance: a review of the literature. Cancers 2023; 15: 1-14.
26.
Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
27.
Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomised, open-label, phase III, noninferiority trial. Ann Oncol 2018; 29: 624-631.
28.
Denda T, Takashima A, Gamoh M, et al. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. Eur J Cancer 2021; 154: 296-306.
29.
Chitkara A, Bakhtiar M, Sahin IH, et al. A meta-analysis to assess the efficacy of HER2-targeted treatment regimens in HER2- positive metastatic colorectal cancer (mCRC). Curr Oncol 2023; 30: 8266-8277.
30.
Tabernero J, Yoshino T, Kim TW, et al. 515MO Encorafenib + cetuximab (EC) + FOLFIRI for BRAF V600E-mutant metastatic colorectal cancer (mCRC): updated results from the BREAKWATER safety lead-in (SLI). ESMO Ann Oncol 2024; 35: 435-436.
31.
Yoshino T, Di Bartolomeo M, Raghav K, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun 2023; 14: 1-13. DOI: 10.1038/s41467-023-38032-4.
32.
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019; 20: 518-530.
33.
Sartore-Bianchi A, Lonardi S, Martino C, et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 2020; 5: 1-8. DOI: 10.1136/esmoopen-2020-000911.
34.
Babkoff A, Zick A, Hubert A, et al. Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future. ESMO Gastrointestinal Oncology 2024; 3: 1-10.
35.
Garralda E, Hong DK, Xu R, et al. Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: an expanded dataset. Ann Oncol 2022; 33: 370. DOI: 10.1016/j.annonc.2022.04.43.
36.
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024. Available at: https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-presents-updated-phase-2-data-for-zanidatamab-demonstrating-increased-mpfs-in-her2-positive-metastatic-gastroesophageal-adenocarcinoma-at-esmo-2024-302248513.html
37.
Garrido-Laguna I, Lonardi S, Bazhenova L, et al. Entrectinib in NTRK fusion-positive gastrointestinal cancers: updated integrated analysis. Ann Oncol 2022; 33: 370-371.
38.
Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020; 383: 813-824.
39.
Kopetz S, Boni V, Kato K, et al. First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2024; 42: 3000. DOI: 10.1200/JCO.2024.42.16_suppl.30.
40.
Hu H, Cai W, Wu D, et al. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. Cancer Med 2021; 10: 135-142.
41.
Bikhchandani M, Amersi F, Hendifar A, et al. POLE-mutant colon cancer treated with PD-1 blockade showing clearance of circulating tumor DNA and prolonged disease-free interval. Genes (Basel) 2023; 14: 1054. DOI: 10.3390/genes14051054.
42.
Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Lancet Gastroenterol Hepatol 2016; 1: 207-216.
43.
Andre T, Elez E, Van Cutsem E, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. Presented at the 2024 Gastrointestinal Cancers Symposium. San Francisco, CA; 2024. DOI: 10.1200/JCO.2024.42.3_suppl.LBA768.
44.
Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18: 1182-1191.
45.
Mauri G, Vitiello PP, Sogari A, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. Br J Cancer 2022; 127: 394-407.
46.
Ohishi T, Kaneko MK, Yoshida Y, Takashima A, Kato Y, Kawada M. Current targeted therapy for metastatic colorectal cancer. Int J Mol Sci 2023; 24: 1702. DOI: 10.3390/ijms24021702.
47.
Bekaii-Saab T. A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer. Am J Manag Care 2024; 30: 23-30.
48.
Yoshino T, Uetake H, Tsuchihara K, et al. PARADIGM study: a multicenter, randomised, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer. J Clin Oncol 2021; 39: 158-163.
49.
Simkens LH, Van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852.
50.
Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PANAMA trial (AIO KRK 0212). J Clin Oncol 2021; 40: 72-82.
51.
Gmeiner WH. Recent advances in our knowledge of mCRC tumor biology and genetics: a focus on targeted therapy development. Onco Targets Ther 2021; 14: 2121-2130.
